Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Huntington disease
Biotech
Novartis pays PTC $1B upfront for midphase Huntington's program
The biotech has built its case for the oral candidate around evidence it reduces levels of the protein in the central nervous system and periphery.
Nick Paul Taylor
Dec 2, 2024 7:53am
uniQure's interim data shows gene therapy slows Huntington’s
Jul 9, 2024 9:25am
Sage's dalzanemdor trial design leaves efficacy question unclear
Jun 11, 2024 8:28am
VectorY raises $138M to push forward ALS program
Nov 13, 2023 10:26am
JPM23: Annexon looks for '2 ways to win' in Huntington's trial
Jan 11, 2023 12:55pm
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Dec 14, 2022 7:15am
